Robert Dudkowiak

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn et al. · Gastroenterology · 2021 · 227 citations

Pharmacy, Immunology, Pharmacotherapy +13

Inflammatory bowel disease meets fertility: A physician and patient survey

Sophie Vieujean, Michel De Vos, Ferdinando D’Amico et al. · Digestive and Liver Disease · 2023 · 26 citations

Medicine, Family Medicine, Immunology +8

Hepcidin and its role in inflammatory bowel disease.

Robert Dudkowiak, Katarzyna Neubauer, Elżbieta Poniewierka · PubMed · 2013 · 22 citations

Medicine, Biochemistry, Pathobiology +17

13C-Methacetin Breath Testing in Patients with Non-Alcoholic Fatty Liver Disease

Radosław Kempiński, Katarzyna Neubauer, Szymon Wieczorek et al. · Advances in Clinical and Experimental Medicine · 2016 · 13 citations · Full text

Medicine, Internal Medicine, Pathology +17

OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis

Shomron Ben‐Horin, Jarosław Leszczyszyn, Robert Dudkowiak et al. · Journal of Crohn s and Colitis · 2020 · 12 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13